Jefferies reiterates Summit Therapeutics stock rating after FDA setback
At a glance
- $SMMT today−9.48%last $10.70
- Vs industry peers−8.45 pts6-peer median −1.02% · far behind
- Since Nov 15+2.20%from the first trade after the story
- 52-week range1.6% above low$10.53 – $29.23
- Cash runway~3 mo$150.8M cash ÷ $47.2M/mo burn · 10-Q
- Coverage3 this week4 in 30 days · too few stories to call a pace
Nothing reported about summit therapeutics across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.
Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.
What it means
- What to watch: In healthcare, timing is everything: trial results, FDA updates, and pricing shifts are the main drivers of stock movement.
- How the stock is trading: $SMMT -9.48% in the latest session.
- Timing: It was published over the weekend. The change shown is Friday's, and Monday is the first session that could react. Market holidays are not detected.
Where the stock stands
Summit Therapeutics ($SMMT) dropped 9.48% to $10.70 in the latest session. Over the past month it is down 31.5%. It now sits 63% under the 52-week high of $29.23 and 1.6% above the year's low of $10.53, close to the bottom of its range. The year's high was 2.8 times its low, which makes double-digit swings fairly routine here.
What the filings say
In its latest report (10-Q, filed Nov 4, 2026), $SMMT lost $208.4M over the quarter to Sep 30, 2026. Operations used $423.2M of cash over the nine months to Sep 30, 2026 — about $47.2M a month — against $150.8M in cash on Sep 30, 2026. At that pace the cash covers about 3 months, which is why financing, asset sales or restructuring tend to come up for companies in this position. Total liabilities were $128.2M against $150.8M of cash on Sep 30, 2026. The company filed an 8-K — the form for material events — on Nov 16, 1 day after this story; it is $SMMT's own account and the first thing to read. Figures are as filed with the SEC; the $SMMT page has the full statements.
How much coverage it is getting
This is one of 4 stories on Summit Therapeutics in Wook's last 30 days of coverage, including 3 this week. That is well above its usual pace: over the month it has averaged about 1 a week. Going by their wording, 0 read bullish, 2 neutral and 2 bearish. This one reads neutral, like most of them. This is the only one from Investing.com; the rest came from other outlets.
The bigger picture
Healthcare moves on the calendar — trial outcomes, FDA decisions, and pricing rules. One drug's result can shift a company's fate; a policy change can ripple across the entire sector. Health Care reads calm on Wook's supply-chain scanner today, with no unusual stress in the filings and disclosures it watches.
What to watch next
For the company's side of it, read its latest SEC filings on the $SMMT page. A US company has to report material news on an 8-K, usually within four business days; foreign issuers use a 6-K. Where several outlets agree is usually the news; where they differ is the angle. To run the numbers yourself, ask Wook AI above about $SMMT: its distance from the high, its last report, or how coverage has changed.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Investing.com published this on November 15, 2026. $SMMT has moved +2.20% ($10.47 to $10.70). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.
